ilShinBioBase Co Ltd

ilShinBioBase maintains a strong liquidity position, as evidenced by its current ratio of 14.28, indicating that the company has significantly more current assets than current liabilities. The company's liquidity is further supported by a substantial cash and equivalents balance of 3,945,137,450 KRW, which provides a buffer against short-term obligations. The absence of long-term debt and a debt-to-equity ratio of 0.0 suggests a conservative capital structure with minimal leverage risk.

In terms of profitability, ilShinBioBase reported a net income of 571,467,310 KRW and an operating income of 118,209,310 KRW, translating to a return on equity of 0.01 and a return on assets of 0.0094. These returns are relatively low compared to industry benchmarks, indicating that the company may not be generating returns at a level that is typical for its sector. The gross profit of 904,349,260 KRW suggests that the company is able to maintain a reasonable margin on its sales, but the operating income margin is relatively thin, which could be a concern for long-term profitability.

The company's revenue concentration is not explicitly detailed in the available data, but the absence of segment-specific revenue breakdowns implies that the business may be concentrated in a single or limited number of product lines or geographic regions. This lack of diversification could pose a risk if demand for the company's primary offerings were to decline or if the company faces regulatory or market challenges in its primary operating region.

Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. However, the company's free cash flow of 679,773,310 KRW indicates that it has the capacity to reinvest in its operations or return value to shareholders. The absence of immediate liquidity or dilution flags suggests that the company is not currently facing significant financial pressures that could impede its growth.

The risk assessment for ilShinBioBase indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's conservative capital structure, with no long-term debt, further supports this assessment. However, the low return on equity and assets suggests that the company may need to improve its operational efficiency or expand its revenue base to enhance profitability.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The last actual EPS reported was 109.00 KRW, which provides a baseline for evaluating the company's earnings performance. The absence of recent major events or filings suggests that the company is operating in a stable environment, but continued monitoring of its financial performance and market conditions is advisable.

Operating income surged 101% year-over-year to 4.5 billion KRW, demonstrating significant operational leverage and profitability expansion.

The company maintains a zero debt-to-equity ratio, providing a pristine balance sheet with minimal financial risk compared to peers.

Revenue grew 34.3% year-over-year to 14.5 billion KRW, signaling strong top-line momentum in the current fiscal period.

Free cash flow increased 25% to 4.9 billion KRW, supporting internal funding capabilities without relying on external capital.

Return on invested capital is merely 0.2%, indicating extremely inefficient capital deployment relative to the capital base.

Net income fell at a 4.9% CAGR over four years, highlighting inconsistent profitability trends over the longer term.

Cash conversion ratio of 0.58 trails the cohort median of 0.79, suggesting weaker quality of earnings relative to peers.

Return on equity of 1% is minimal, reflecting limited ability to generate substantial returns for shareholders on book value.